Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 6,127

Document Document Title
WO/2009/146539A1
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...  
WO/2009/145989A2
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2009/069132A3
Compounds that are capable of inhibiting an activity of a reverse transcriptase are disclosed. Further disclosed are pharmaceutical compositions containing these compounds, and methods of inhibiting an activity of reverse transcriptase a...  
WO/2009/132978A1
This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula (I) wherein A1, A2, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compo...  
WO/2009/130422A2
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...  
WO/2009/130317A1
The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the ...  
WO/2008/145615A3
The present invention relates to the use of aminoazoline and urea derivatives for com- bating animal pests. The invention also relates to a method for controlling animal pests by using these compounds, to seed and to an agricultural and ...  
WO/2009/121603A1
The invention relates to a method for producing at least one compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with an alcoh...  
WO/2009/121607A1
The invention relates to a method for producing a compound having at least one at least monosubstituted amino group. According to the invention, a starting substance supporting at least one amino group is reacted with a reagent supportin...  
WO/2009/124022A1
The invention provides amino- and amido-aminotetralin compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opio...  
WO/2009/121843A1
Process for increasing the capacity of an existing urea plant comprising a high-pressure urea synthesis section and one or more recovery sections, wherein next to the existing urea plant a urea production unit, comprising a high-pressure...  
WO/2009/089541A3
A method for designing a molecule capable of functioning as a PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a...  
WO/2009/115491A1
The present invention relates to azolin-2-ylamino compounds of formulae (I) and (II), wherein n is 0 to 3; Ar is phenyl; A is a radical of formulae A1 or A2, wherein * indicates the point of attachment; X is S, O or N(R10); R7a-d are H, ...  
WO/2009/053443A3
This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.  
WO/2009/117095A1
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are...  
WO/2009/115040A1
Benzoylurea compounds having the structure of formula (I) and uses thereof, wherein: R1 and R2 are independently selected from H, F, Cl, Br and I; R3, R4, R5, R6 and R7 are independently selected from H, halogen, C1-C6alkyl, C1-C6alkoxyl...  
WO/2009/106351A1
The present invention provides a compound of formula (I): wherein: R1 is a group selected from -CH2OH1-NHCOH and R2 is a hydrogen atom; or R1 together with R2 form the group -NHC(O)CH=CH-, wherein the nitrogen atom is bound to the carbon...  
WO/2008/116145A3
Disclosed are urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The co...  
WO/2009/096526A1
Provided is a compound having a CRTH2 antagonism and being useful as a preventive and/or remedy for inflammatory diseases (for example, asthma, allergic rhinitis, allergic dermatitis, conjunctivitis, urticaria, eosinophilic bronchitis, f...  
WO/2009/096505A1
There have been required drugs, health foods and so on whereby subjective symptoms, for example, decline in clear thinking, defocusing and decline in memory of trivial matters can be reduced and the quality of life of people having these...  
WO/2009/095164A1
The invention relates to a method for producing urethanes by the oxidative carbonylation of amino compounds in the presence of carbon monoxide, oxygen and organic compounds carrying hydroxyl groups, characterized in that the carbonylatio...  
WO/2009/034308A3
There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R' is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). Ther...  
WO/2009/089192A1
The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):  
WO/2009/089541A2
A method for designing a molecule capable of functioning as a PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a...  
WO/2009/086429A1
Disclosed are amide and urea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compo...  
WO/2009/081892A1
Disclosed is a compound represented by the general formula (I) below which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing such a compound or...  
WO/2009/015485A8
A CPTl inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural ...  
WO/2008/156816A3
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...  
WO/2009/071533A1
The present invention relates to novel polyisocyanates containing allophanate groups and based on isophorone diisocyanate and use thereof.  
WO/2009/072798A1
A high adhesive acrylate monomer has a specific chemistry figure. This monomer may be easily prepared in a simplified way, and various linkers may be used between L-DOPA and an acrylate group attached to a tail of L-DOPA, so molecular we...  
WO/2009/069132A2
Compounds that are capable of inhibiting an activity of a reverse transcriptase are disclosed. Further disclosed are pharmaceutical compositions containing these compounds, and methods of inhibiting an activity of reverse transcriptase a...  
WO/2009/067597A1
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.  
WO/2009/063804A1
Disclosed is a process for producing N-carbamoyl-tert-leucine, which is characterized by mixing tert-leucine with an isocyanic acid compound in an amount of 0.9 to 1.1 times the amount of tert-leucine by mole, while keeping the pH value ...  
WO/2009/039361A3
(S)-2-(3-tert-Butylureido)-3,3-dimethylbutanoic acid is conveniently prepared in a single reaction vessel from commercially available starting materials in a process that can be run on a kilogram or larger scale.  
WO/2006/014405A3
Various sulfonamide-based compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteopor...  
WO/2009/053443A2
This invention provides new indane compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.  
WO/2006/071940A3
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulatio...  
WO/2009/013915A8
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...  
WO/2009/050041A1
The present invention relates to carbamoylglycine derivatives, a process for the preparation of carbamoylglycine derivatives and the use of carbamoylglycine derivatives in the preparation of enantiomerically enriched α-amino acids. Furt...  
WO/2003/082205A3
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...  
WO/2009/045830A1
This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition cont...  
WO/2005/041684A3
The present invention relates to the discovery that certain non-naturally occurring, non-peptide arride compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavorin...  
WO/2009/024493A3
The invention relates to a novel alkenyl isocyanate characterized by the chemical formula (I). Said compound is obtained by converting isophorone diisocyanate with N-(t-butyl) aminoethyl methacrylate. The novel compound is particularly s...  
WO/2008/122667A3
The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.  
WO/2009/041482A1
Disclosed is an acetylene compound represented by the general formula (1) below, which is useful as a raw material for fused polymers having high heat resistance. (In the formula (1), the encircled Ar represents an aryl group or a hetero...  
WO/2009/034308A2
There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R' is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). Ther...  
WO/2009/035928A1
Disclosed are amide, thoiamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and co...  
WO/2009/030752A1
The present invention relates to compounds of formula (I) : as well as to cosmetic and pharmaceutical compositions containing such a compound.  
WO/2009/030746A1
The present invention relates to compounds of formula (I): and to the cosmetic and pharmaceutical compositions containing such a compound.  
WO/2008/156816A8
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to ...  

Matches 301 - 350 out of 6,127